BIOLIFE SOLUTIONS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $96.2 | $74.6 | $68.0 | $76.2 | $119.2 |
| Operating income | -$16.6 | -$4.5 | -$17.2 | -$5.9 | -$35.2 |
| Net income | -$4.6 | -$20.2 | -$68.0 | -$139.8 | -$8.9 |
| Balance Sheet | |||||
| Total debt | $5.0 | $16.0 | $23.9 | $25.8 | $7.2 |
| Cash Flow Statement | |||||
| Free cash flow | $10.6 | $5.2 | -$18.9 | -$18.9 | -$13.0 |
Shares outstanding 48.9M · Free float 83.0%
Annual filing data through FY ended December 31, 2025; float as of October 7, 2026.
Coverage
October 6, 2026
Deals
Repligen Completes $1.5 Billion BioLife Solutions Acquisition
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 23, 2026
Deals
Repligen to Buy BioLife in $1.5 Billion Cash-and-Stock Deal
July 22, 2026
Deals
Repligen to Buy BioLife Solutions in $1.5 Billion Mixed Deal